COVID-19 is a contagious disease caused by severe acute respiratory syndrome coronavirus 2.
Symptoms of COVID-19 are variable, but often include fever, cough, fatigue, breathing difficulties, and loss of smell and taste. Symptoms begin one to fourteen days after exposure to the virus. Multi-year studies are underway to further investigate the long-term effects of the disease.
To enhance your search results you can use the various filters available such as mode (online/ on-site).
Indian Medical Association Assam welcomes doctors to a recorded live clinical experience sharing webinar session on "Early action in COVID-19-The benefits". IMA A...
Indian Medical Association Maharashtra welcomes you to listen in to a recorded webinar on the topic of "Case studies on treatment of mild-moderate COVID 19-lessons learnt"....
Cases of COVID-19 are steadily rising in India, and because there is limited clinical experience around treatment options it becomes critical to share knowledge. Indian Medical Associatio...
IMA-Uttarakhand and IMA Himachal Pradesh welcome doctors to an interactive experience sharing recorded session on “Reinfection in COVID-19 patients; experience sharing and ex...
HIGHLIGHTS OF THE WEBINAR MODULE 1 - Overview of COVID-19, Dr B B Revari (30min) •Microbiology of corona virus, virus history with types and pathophysiology. •Description of t...
IMA Chandigarh welcomes you to recorded webinar session on “Treating Mild to Severe COVID-19 Patients” What was covered: Introduction of panelist: Dr. Mayuri Keskar, MLH & TC4A...
IMA-Karnataka welcomes doctors to this informative recorded session on "Use of Remdesivir in treating patients with COVID-19 (Experience sharing & Updates from Clinical Trials)" Intro...
Recording of the webinar is not available
Remdesivir , is approved in India for the treatment of suspected or laboratory confirmed incidences of COVID-19 in adults and children hospitalized with severe presentations of the disease....
As the incidence of COVID-19 cases continue to rise, we will need multiple approaches to effectively deal with this pandemic. Clinicians are evaluating Favipiravir for use in mild-to-moderat...
